Epizyme

$13.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (+0.69%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Epizyme and other stocks, options, and ETFs commission-free!

About EPZM

Epizyme, Inc. Common Stock, also called Epizyme, is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. The listed name for EPZM is Epizyme, Inc. Common Stock.

CEO
Robert B. Bazemore
Employees
203
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
1.33B
Price-Earnings Ratio
Dividend Yield
Average Volume
846.31K
High Today
$13.36
Low Today
$12.81
Open Price
$13.08
Volume
676.43K
52 Week High
$27.82
52 Week Low
$9.90

Collections

EPZM Earnings

-$0.74
-$0.49
-$0.25
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 26, Pre-Market

You May Also Like